Top 3 GDPR Compliance Questions in Clinical Trials
In the fast-evolving world of clinical trials, GDPR compliance is more than a legal obligation—it’s a pillar of trust,...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trial Quality Clinical Trials CLINOPS WATCHDOG CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
In the fast-evolving world of clinical trials, GDPR compliance is more than a legal obligation—it’s a pillar of trust,...
Oncomatryx, a biopharmaceutical company developing antibody-drug conjugates (ADCs), secured €25 million to advance clinical trials of OMTX705, a first-in-class...
LIB Therapeutics‘ Phase 3 LIBerate-HoFH study results for lerodalcibep, a novel PCSK9 inhibitor, in patients with homozygous familial hypercholesterolemia...
Quince Therapeutics announced the publication of long-term safety data from Ataxia-Telangiectasia (A-T) patients treated with EryDex for at least...
ILiAD Biotechnologies and hVIVO will collaborate on a Phase 3 human challenge trial for ILiAD’s next-generation intranasal pertussis vaccine,...
RenovoRx announced promising pharmacokinetic data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial, investigating its Trans-Arterial...
Cartesian Therapeutics (NASDAQ: RNAC) received FDA approval under the Special Protocol Assessment (SPA) process for the Phase 3 AURORA...
Adagene Inc. announced positive updated clinical data for ADG126 (muzastotug), an anti-CTLA-4 SAFEbody® drug, combined with pembrolizumab in a...
Ocugen has received FDA approval to begin a Phase 1 clinical trial for OCU500, an inhaled and nasal spray...
Novotech, a full-service international contract research organization (CRO), released a white paper analyzing global clinical trial trends in oncolytic...